Gastrointestinal Cancer

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the treatment landscape in newly diagnosed metastatic colorectal cancer (mCRC).

Manish A. Shah, MD, discusses the results of the GAMMA-1 trial and challenges that remain for patients with gastric cancer.

Byrne Lee, MD, chief, Upper GI and Mixed Tumor Surgery Service, associate professor of surgical oncology, City of Hope, discusses the differences between HIPEC and PIPAC in the treatment of patients with metastatic colorectal cancer.

Thanks to technological advances, the past several decades have witnessed a blossoming appreciation of the varied composition of these microbial communities, their complex and dynamic relationship with the host, and the way they affect health and disease.

Byrne Lee, MD, discusses regional treatment strategies for patients with metastatic colorectal cancer.

SM-88, a novel compound that attacks oncogenic metabolic pathways, is under development for patients with metastatic pancreatic cancer and other solid tumors, raising the potential for a tumor-agnostic therapy.